The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
|Webcasts|August 12, 2020
Discover Functional Film Coating Formulations for an Easy and Fast Coating Process of SODFs
Author(s)BIOGRUND
What are the reasons for functional film coating of solid oral dosage forms? How do polymers influence the release of active ingredients in a tablet coating? Abderraouf Allia uses many practical examples and different formulations to show what needs to be taken into account during formulation. Participate in this webcast and learn how ready-to-use film coating systems can simplify the coating and formulation process. Live: Wednesday, Sept. 16, 2020 at 10 am EDT | 9am CDT | 3pm BST | 4pm CEST On demand available after airing until Sept. 16, 2021
Register free:
Event Overview:
Functional film coatings can be applied to solid oral dosage form (SODF) drugs to mask taste or odor, provide a moisture barrier, offer enteric protection, or modify the release of the drug.
This webcast will review several formulation examples, case studies, and how film coatings are applied and processed. The application of ready-to-use film coatings will be explained.
Learn which formulation can be used for reliable odor and taste masking or how the dissolution profile of an API tablet can be modified. In addition, the properties of different coating formulations will be investigated.
Key Learning Objectives:
- Understand the function of polymers for taste and odor masking, moisture barriers, enteric protection, modified release
- Learn how hygroscopic tablet cores can be protected
- Discover the benefits of ready-to-use film coating formulations
Speaker: Abderraouf Allia, Business Development Manager, BIOGRUND
Time and date: Wednesday, Sept. 16, 2020 at 10 am EDT | 9am CDT | 3pm BST | 4pm CEST
On demand available after airing until Sept. 16, 2021
Sponsor: BIOGRUND
Register free:
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.